Adding relatlimab to nivolumab and chemotherapy improved efficacy but did not increase safety concerns in advanced-stage lung cancer. The addition of relatlimab to nivolumab (Opdivo)—a combination ...

a fixed-dose combination of LAG-3 drug relatlimab with PD-1 inhibitor nivolumab, sold on its own as Opdivo. So far, that is only approved to treat melanoma but has grown quickly to reach $627 ...

LAG-3 drugs from arch-rivals Bristol-Myers Squibb ... with results showing a single infusion of its LAG-3 blocker relatlimab and its Opdivo immunotherapy improved progression-free survival in ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

After hours: September 19 at 6:49 PM EDT Loading Chart for HALO ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or ...

Despite the potential competitive advantage of nivolumab (nivo), relatlimab, and chemotherapy in first-line non-small cell lung cancer (NSCLC), there are reservations about the market’s ...

A clinical trial involves the study of the safety, efficacy and/or dosage regimen of a therapeutic intervention (such as a drug) in humans selected according to predetermined criteria of ...

This section provides information about our role and the legal responsibilities of healthcare providers that handle controlled drugs. View our latest report on the safer use of controlled drugs which ...